A股異動丨永太科技漲6.45% 吉利德的新冠治療藥物可能很快獲得FDA批准
格隆匯3月19日丨永太科技(002326.SZ)漲6.45%,報12.7元,總市值111.63億元。Piper Sandler分析師Tyler Van Buren週三表示,吉利德的治療藥物“可能很快會被批准用於新冠病毒”,此前他表示富士膠片研發的類似藥物用於200名患者,得出了“非常鼓舞人心”的數據。“我們現在認為瑞德西韋臨牀試驗結果可能是積極的”。他説:“如果成功,如果它是安全的,在病毒全球大流行背景下療效門檻會比較低,未來幾個月內可能被批准廣泛使用”。永太科技上個月曾表示,無論是為吉利德還是為國內藥廠在專利許可下的生產,均有能力快速提供瑞德西韋中間體產品。而同時,永太科技也告知投資者,公司與吉利德正在積極洽談合作事宜,尚未簽署相關協議,合作的達成尚存在不確定性。永太科技董祕還表示,在收到吉利德業務詢盤(達成合作前的接洽)時,吉利德瞭解到永太科技可以提供的瑞德西韋各中間體片段工藝技術,及產業化生產情況,特別詢問了其中比較關鍵的中間體的報價及交貨時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.